NASDAQ:NLTX Neoleukin Therapeutics (NLTX) Stock Price, News & Analysis $48.37 +0.17 (+0.35%) (As of 10/25/2024) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsInsider TradesOwnershipSEC FilingsTrends About Neoleukin Therapeutics Stock (NASDAQ:NLTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Neoleukin Therapeutics alerts:Sign Up Key Stats Today's Range$47.76▼$50.8550-Day Range$34.38▼$52.9252-Week Range$2.03▼$14.36Volume80,712 shsAverage Volume50,104 shsMarket Capitalization$454.58 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNeoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.Read More… 24/7 Automated Profits in Crypto (Ad)What if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast world of passive crypto income, where you set up a dependable income stream that works for you, whether you're at your computer or living your life.>> Secure Your Spot On The Groundbreaking Workshop Here Receive NLTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neoleukin Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NLTX Stock News HeadlinesComparing Nuvation Bio (NYSE:NUVB) and Neoleukin Therapeutics (NASDAQ:NLTX)October 23, 2024 | americanbankingnews.comIs Neoleukin Therapeutics (NASDAQ:NLTX) In A Good Position To Invest In Growth?December 20, 2023 | finance.yahoo.comUrgent: This election is riggedIf you missed it, my emergency election broadcast is now available - but will be removed soonOctober 29, 2024 | Porter & Company (Ad)Neoleukin Therapeutics Announces 1-for-4 Reverse Stock SplitDecember 15, 2023 | finance.yahoo.comNeoleukin Therapeutics Stock (NASDAQ:NLTX) Dividends: History, Yield and DatesDecember 4, 2023 | benzinga.comPre-market Movers: ORTX, CMBM, GROM, RSVR, FEMY…October 5, 2023 | markets.businessinsider.comNeoleukin Therapeutics, Inc.: Neoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitSeptember 26, 2023 | finanznachrichten.deNeoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitSeptember 22, 2023 | finance.yahoo.comSee More Headlines NLTX Stock Analysis - Frequently Asked Questions How have NLTX shares performed this year? Neoleukin Therapeutics' stock was trading at $19.38 at the beginning of the year. Since then, NLTX stock has increased by 149.6% and is now trading at $48.37. View the best growth stocks for 2024 here. How were Neoleukin Therapeutics' earnings last quarter? Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) announced its quarterly earnings results on Thursday, November, 4th. The company reported ($5.60) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($5.60). When did Neoleukin Therapeutics' stock split? Shares of Neoleukin Therapeutics reverse split before market open on Tuesday, December 19th 2023. The 1-4 reverse split was announced on Tuesday, December 19th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 19th 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. How do I buy shares of Neoleukin Therapeutics? Shares of NLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Neoleukin Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neoleukin Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), General Electric (GE) and CrowdStrike (CRWD). Company Calendar Last Earnings11/04/2021Today10/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NLTX CUSIPN/A CIK1404644 Webwww.neoleukin.com Phone(866) 245-0312Fax778-331-4486Employees90Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.11) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-57,560,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-37.22% Return on Assets-30.91% Debt Debt-to-Equity RatioN/A Current Ratio15.33 Quick Ratio15.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.08 per share Price / Book4.37Miscellaneous Outstanding Shares9,398,000Free Float9,250,000Market Cap$454.58 million OptionableNo Data Beta1.11 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:NLTX) was last updated on 10/29/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk Drops Stunning Bombshell?Elon Musk just dropped a BOMBSHELL that could send shockwaves throughout the tech industry… While deliverin...Paradigm Press | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neoleukin Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neoleukin Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.